Karna D Shinde, an early-stage angel investor, has made an undisclosed investment in Navaux, a life science company located in Arkansas, USA.
Navaux is a specialist in the early detection of cancer and the monitoring of treatment, employing a state-of-the-art blood test known as ACTIVH.
The ACTIVH test, which was developed by Navaux based on extensive preclinical research, has the potential to predict the onset of cancer up to 3-4 years in advance. This early detection enables individuals to implement critical lifestyle modifications that may potentially avert the development of cancer.
Elevated Hepsin levels, which are indicative of the presence of tumors, are detected through a straightforward blood draw in this noninvasive, rapid, and straightforward testing procedure.
Read also - Nasher Miles Raises $4 Mn Series A Funding Round
Finance Minister Nirmala Sitharaman's recent declaration of the Union Budget 2024-25 underscores the fact that India is rapidly turning into a center for health-tech innovations. In order to enhance access to essential treatments, this budget waives customs duty on three essential cancer treatment medications.
Karna D Shinde's investment in Navaux extends beyond pecuniary assistance. He contributes invaluable insights and a hands-on approach to the company's expansion.
Want to go deeper into the world of startups and entrepreneurship? Check out these categories on VIESTORIES:
Startup Success Stories: Discover inspiring tales of startups overcoming challenges and achieving success.
Funding Startup News: Stay updated with the latest news and trends in startup funding and investment.
Startup Insights: Dive into in-depth analyses of various industries and market trends to make informed business decisions.